aPatients need PA approved by second fill and insurance must continue to cover the claim for patients to pay as little as $0 for up to 12 months.
Please work with the patient's plan to pursue claim approval by the second fill. Patients need approval by second fill to continue to pay as little as $0 for REYVOW.
Message and data rates apply.
To participate in the REYVOW Program, patients can call 1-833-656-1058, and we will guide them through the reimbursement process. If all documentation is complete and eligibility criteria is met, we will send a reimbursement check to your patient within 3 weeks of receiving the required information. Your patients can find more information about the REYVOW Program at reyvow.com/savings-support.
A form to help you prescribe REYVOW for your patients.
A quick guide to completing the REYVOW prior authorization request for you and your office staff.
A sample letter to appeal coverage determination or prior authorization for a patient’s plan.
A sample letter with Letter of Medical Necessity considerations.
An overview for pharmacists that combines relevant product and savings information.
If interested in requesting a visit from a REYVOW sales representative or a REYVOW sample pack, please complete and submit your request electronically
REYVOW sample packs provide patients and healthcare professionals the opportunity to determine if REYVOW is right for the patient. Samples are used to assess the product’s efficacy and tolerability for an individual patient. Not all states accept controlled substance samples. REYVOW is a Schedule V controlled substance.
INDICATION AND USAGE
REYVOW is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: REYVOW is not indicated for the preventive treatment of migraine.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
REYVOW may cause significant driving impairment. In a driving study, administration of single 50 mg, 100 mg, or 200 mg doses of REYVOW significantly impaired subjects' ability to drive. Additionally, more sleepiness was reported at 8 hours following a single dose of REYVOW compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW.
Central Nervous System Depression
REYVOW may cause central nervous system (CNS) depression, including dizziness and sedation. Because of the potential for REYVOW to cause sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants. Patients should be warned against driving and other activities requiring complete mental alertness for at least 8 hours after REYVOW is taken.
In clinical trials, reactions consistent with serotonin syndrome were reported in patients treated with REYVOW who were not taking any other drugs associated with serotonin syndrome. Serotonin syndrome may also occur with REYVOW during coadministration with serotonergic drugs. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular signs, and/or gastrointestinal signs and symptoms. The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue REYVOW if serotonin syndrome is suspected.
Medication Overuse Headache
Overuse of acute migraine drugs may lead to exacerbation of headache. Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.
The most common adverse reactions associated with REYVOW (≥2% and greater than placebo in clinical studies) were dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, and muscle weakness.